Measurement of complexed PSA improves specificity for early detection of prostate cancer

Urology

Volumn 52, Issue 3, 1998, Pages 372-378

  Brawer, Michael K ^a   Meyer, Grant E ^b   Letran, Jason L ^b   Bankson, Dan D ^b   Morris, Deborah L ^b   Yeung, Kwok K ^b   Allard, W Jeffrey ^b  

^a NORTHWEST HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0032169746     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00241-6     Document Type: Article

References (40)

1. 1. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of PSA in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
2. 2. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with PSA. J Urol 147: 841-845, 1992.
3. 3. Brawer MK, Beatie J, Wener MH, et al: Screening for prostatic carcinoma with PSA: results of the second year. J Urol 150: 106-109, 1993.
4. 4. Carter H, Morrell CH, Pearson JD, et al: Estimation of prostatic growth using serial PSA measurements in men with and without prostate disease. Cancer Res 52: 3323-3328, 1992.
5. 5. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
6. 6. Smith DS, and Catalona WJ: Rate of change in serum prostate specific-antigen levels as a method for prostate cancer detection. J Urol 152: 1168-1169, 1994.
7. 7. Rommel FM, Augusta VE, Breslin JA, et al: The use of PSA and PSAD in the diagnosis of prostate cancer in a community based urology practice. J Urol 151: 88-93, 1994.
8. 8. Benson MC, Whang IS, Olsson CA, et al: The use of PSA density to enhance the predictive value of intermediate levels of serum PSA. J Urol 147: 817-821, 1992.
9. 9. Benson MC, Whang IS, Pantuck A, et al: Prostate-specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815-816, 1992.
10. 10. Maeda H, Ishitoya S, Maekawa S, et al: Prostate specific antigen density of the transition zone in the detection of prostate cancer. J Urol 157: 58A, 1997.
11. 11. Zlotta AR, Djavan B, Marberger M, et al: Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 157: 1315-1321, 1997.
12. 12. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum PSA in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
13. 13. Dalkin BL, Ahmann FR, and Kopp JB: PSA levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150: 1837-1839, 1993.
14. 14. Porter JR, Hayward R, and Brawer MK: The significance of short-term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 151: 293A, 1994.
15. 15. Riehman M, Rhodes PR, Cook TD, et al: Analysis of variation in prostate-specific antigens. Urology 42: 390, 1993.
16. 16. Nixon RG, Wener MH, Smith KM, et al: Biological variation of prostate-specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 157: 2183-2190, 1997.
17. 17. Brawer MK, Aramburu EAG, Chen GL, et al: The inability of PSA index to enhance the predictive value of PSA in the diagnosis of prostatic carcinoma. J Urol 150: 369-373, 1993.
18. 18. Catalona WJ, Richie JP, deKernion JB, et al: Comparison of PSA concentrations versus PSA density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2031-2036, 1994.
19. 19. Mettlin C, Littrup PJ, Kane RA, et al: Relative sensitivity and specificity of serum PSA level compared with age-referenced PSA, PSA density and PSA change. Cancer 74: 1615-1620, 1994.
20. 20. Keetch DW, McMurtry JM, Smith DS, et al: Prostate-specific antigen density versus prostate-specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 156: 428-431, 1996.
21. 21. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal PSA cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2037-2042, 1994.
22. 22. Etzioni R, Shen Y, Petteway JC, et al: Age-specific PSA: a reassessment. Prostate 7: 70-77, 1996.
23. 23. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of prostate-specific antigen and its reaction with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
24. 24. Lilja H, Christensson A, Dahlen U, et al: PSA in human serum occurs predominantly in complex with alpha-1 antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
25. 25. Stenman U, Leinonen J, Alfthan H, et al: A complex between PSA and α 1-antichymotrypsin is the major form of PSA in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
26. 26. Christensson A, Bjork T, Nilsson O, et al: Serum prostate-specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
27. 27. Luderer AA, Chen Y, Thiel R, et al: Measurement of the proportion of free to total PSA improves diagnostic performance of PSA in the diagnostic gray zone of total PSA. Urology 46: 187-194, 1995.
28. 28. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
29. 29. Bangma CH, Kranse R, Blijenberg BG, et al: The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology 46: 773-778, 1995.
30. 30. Prestigiacomo AF, Lilja H, Pettersson K, et al: A comparison of the free fraction of serum prostate-specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 156: 350-354, 1996.
31. 31. Thiel RP, Oesterling JE, Wojno KJ, et al: Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 48: 45-50, 1996.
32. 32. Catalona WJ, Partin AW, Slawin KM, et al: A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J Urol 157: 111A, 1997.
33. 33. Partin AW: Analysis of percent free PSA for prostate cancer detection: influence of total PSA, prostate volume and age. Urology 48: 55-61, 1996.
34. 34. Wang TJ, Linton HJ, Payne J, et al: Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA-ACT. J Urol 157: 147A, 1997.
35. 35. Melchior SW, and Brawer MK: Role of transrectal ultrasound and prostate biopsy. J Clin Ultrasound 24: 463-471, 1996.
36. 36. Wang TJ, Hill TM, Sokoloff RL, et al: Dual monoclonal antibody immunoassay for free prostate-specific antigen. Prostate 28: 10-16, 1996.
37. 37. Woodrum DL, Brawer MK, Partin AW, et al: Interpretation of free prostate-specific antigen clinical research studies for the detection of prostate cancer. J Urol 159: 5-12, 1998.
38. 38. Petteway JC, Brawer MK, and Meyer GE: Comparison of two investigative assays for the free form of PSA. J Urol 155: 371A, 1996.
39. 39. Brawer MK, Bankson DD, Haver VM, et al: Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method. Prostate 30: 269-273, 1997.
40. 40. Murphy GP, Barren RJ, Erickson SJ, et al: Evaluation and comparison of two new prostate carcinoma markers. Cancer 78: 809, 1996.